← Back to Search

Average intake for Sarcopenia

Phase 2
Waitlist Available
Led By Steven E Riechman, PhD, MPH
Research Sponsored by Texas A&M University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 12 weeks of resistance training
Awards & highlights

Study Summary

The purpose of this study is to examine the effect of dietary cholesterol administered as whole egg or egg white (control)on muscle mass gain with resistance training in a young old population of men and women (age 50-69). It is hypothesized that dietary cholesterol will be significantly associated to muscle mass gain.

Eligible Conditions
  • Cardiovascular Disease
  • Sarcopenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 12 weeks of resistance training
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 12 weeks of resistance training for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary: Strength and muscle gain (DEXA)
Secondary outcome measures
Secondary: Blood lipids, inflammatory markers, blood pressure

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: High intakeExperimental Treatment2 Interventions
800 mg/day dietary cholesterol, resistance training, sedentary
Group II: Average intakeExperimental Treatment2 Interventions
400 mg/day dietary cholesterol, resistance training, sedentary
Group III: PlaceboPlacebo Group2 Interventions
< 200 mg/day dietary cholesterol, resistance training, sedentary
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Resistance Training
2019
Completed Phase 2
~1190
Sedentary
2011
Completed Phase 2
~18730

Find a Location

Who is running the clinical trial?

Texas A&M UniversityLead Sponsor
140 Previous Clinical Trials
24,070 Total Patients Enrolled
Steven E Riechman, PhD, MPHPrincipal InvestigatorTexas A&M University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Apr 2025